Vaxcyte, Inc. (NASDAQ:PCVX) Receives $145.71 Average Price Target from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given an average rating of “Buy” by the eight analysts that are covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $145.71.

PCVX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $81.06 on Monday. Vaxcyte has a 1 year low of $58.10 and a 1 year high of $121.06. The firm has a market cap of $10.10 billion, a PE ratio of -17.62 and a beta of 0.98. The stock has a fifty day moving average price of $91.23 and a 200-day moving average price of $93.31.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company posted ($0.91) EPS. As a group, equities analysts anticipate that Vaxcyte will post -4.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now owns 205,695 shares of the company’s stock, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total transaction of $457,450.00. Following the sale, the senior vice president now directly owns 28,697 shares in the company, valued at $2,625,488.53. This trade represents a 14.84 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,732 shares of company stock valued at $11,730,787. Company insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors have recently made changes to their positions in PCVX. Riverview Trust Co bought a new position in shares of Vaxcyte in the 3rd quarter worth $27,000. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the last quarter. Quest Partners LLC bought a new position in shares of Vaxcyte in the 2nd quarter worth $70,000. Meeder Asset Management Inc. grew its holdings in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. bought a new position in shares of Vaxcyte during the 3rd quarter valued at $92,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.